{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:31:48Z","timestamp":1792067508448,"version":"4.4.0"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Anthracyclines remain an essential component of the treatment of many hematologic and solid organ malignancies, but has important implications on cardiovascular disease. Anthracycline induced cardiotoxicity (AIC) ranges from asymptomatic LV dysfunction to highly morbid end- stage heart failure. As cancer survivorship improves, the detection and treatment of AIC becomes more crucial to improve patient outcomes. Current treatment modalities for AIC have been largely extrapolated from treatment of conventional heart failure, but developing effective therapies specific to AIC is an area of growing research interest. This review summarizes the current evidence behind the use of neurohormonal agents, dexrazoxane, and resynchronization therapy in AIC, evaluates the clinical outcomes of advanced therapy and heart transplantation in AIC, and explores future horizons for treatment utilizing gene therapy, stem cell therapy, and mechanism-specific targets.<\/jats:p>","DOI":"10.3389\/fcvm.2022.863314","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:51:36Z","timestamp":1650588696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Novel Therapeutics for Anthracycline Induced Cardiotoxicity"],"prefix":"10.3389","volume":"9","author":[{"given":"Jacqueline T.","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Stein-Merlob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0344-0338(86)80079-6","article-title":"Anthracycline induced myocardial damage: an analysis of 16 autopsy cases.","volume":"181","author":"Kajihara","year":"1986","journal-title":"Pathol Res Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/jcp.34.6.602","article-title":"Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis.","volume":"34","author":"Fitter","year":"1981","journal-title":"J Clin Pathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin- induced cardiomyopathy.","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Investig."},{"key":"B5","doi-asserted-by":"publisher","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","article-title":"Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling.","volume":"111","author":"Dhingra","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets.","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Fail Rev."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010358","article-title":"Oxidative stress-responsive microRNAs in heart injury.","volume":"21","author":"Kura","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.658900","article-title":"Epigenetic mechanisms involved in the cardiovascular toxicity of anticancer drugs.","volume":"8","author":"Papazoglou","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity.","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radial release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications.","volume":"27","author":"Sobczuk","year":"2020","journal-title":"Heart Fail Rev."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2010.07.097","article-title":"Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.","volume":"142","author":"Hiona","year":"2011","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B13","first-page":"382","article-title":"Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats.","volume":"60","author":"Iqbal","year":"2008","journal-title":"Pharmacol Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/ac.67.1.2146570","article-title":"Cardioprotective effects of zofenopril, enalapril, and valsartan against ischaemia\/reperfusion injury as well as doxorubicin cardiotoxicity.","volume":"67","author":"Bozcali","year":"2012","journal-title":"Acta Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on epirubin-induced inflammation and oxidative stress assessed by serial strain rate.","volume":"2","author":"Dess\u00ec","year":"2013","journal-title":"Springerplus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J."},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-0722-6","article-title":"Strategies to prevent cardiotoxicity.","volume":"21","author":"Graffagnino","year":"2020","journal-title":"Curr Treat Options Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity\u2014a systematic review and meta-analysis of carvedilol.","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/cvr\/cvx078","article-title":"Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity.","volume":"114","author":"Lother","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cvr\/cvx162","article-title":"Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.","volume":"114","author":"Hullin","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaccao.2019.10.001","article-title":"Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer.","volume":"1","author":"Davis","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy.","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"B28","author":"Herrmann","year":"2021","journal-title":"Autophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial [Internet]."},{"key":"B29","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaccao.2020.09.007","article-title":"Dual angiotensin receptor-neprilysin inhibition with sacubitril\/valsartan attenuates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity.","volume":"2","author":"Boutagy","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril\u2013valsartan in cancer patients with heart failure.","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B31","first-page":"4","article-title":"SacVal in CTRCD breast cancer.","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardio Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-021-00115-w","article-title":"Rationale and design of the PRevention of cArdiac dysfunction during adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardio Oncol."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3253","article-title":"SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, leukotrienes\/interleukin 6 axis and mTORC1 \/Fox01\/3a mediated apoptosis.","volume":"41","author":"Quagliariello","year":"2020","journal-title":"Eur Heart J."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction.","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","article-title":"Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways.","volume":"21","author":"Bar\u0131\u015f","year":"2021","journal-title":"Cardiovasc Toxicol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","article-title":"Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation.","volume":"14","author":"Jirkovsk\u00fd","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-021-00109-8","article-title":"Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model.","volume":"7","author":"Noel","year":"2021","journal-title":"Cardio Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/jco.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane <) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy.","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","article-title":"Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the children\u2019s oncology group randomized trial pediatric oncology grou.","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease.","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the dana-farber cancer institute ALL consortium.","volume":"47","author":"Vrooman","year":"2011","journal-title":"Eur J Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer.","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0050-9","article-title":"Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the children\u2019s oncology group.","volume":"5","author":"Kopp","year":"2019","journal-title":"Cardio Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardio Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice.","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2010.04.008","article-title":"Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy.","volume":"150","author":"Sharma","year":"2011","journal-title":"Int J Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2011.65","article-title":"Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.","volume":"2","author":"Huelsenbeck","year":"2011","journal-title":"Cell Death Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/15376516.2012.678406","article-title":"Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats.","volume":"22","author":"Kim","year":"2012","journal-title":"Toxicol Mech Methods."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic statin administration may attenuate early anthracycline associated declines in left ventricular ejection function.","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can J Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracycline-or trastuzumab-based chemotherapy for early breast cancer: a propensity score\u2013matched cohort study.","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B56","doi-asserted-by":"publisher","first-page":"H213","DOI":"10.1152\/ajpheart.00646.2016","article-title":"Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.","volume":"312","author":"Chen","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jelectrocard.2019.02.009","article-title":"Effects of high-intensity interval training on the expression of microRNA-499 and pro- and anti-apoptotic genes in doxorubicin-cardiotoxicity in rats.","volume":"55","author":"Alihemmati","year":"2019","journal-title":"J Electrocardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.3390\/curroncol28050351","article-title":"Exercise to reduce anthracycline-mediated cardiovascular complications in breast cancer survivors.","volume":"28","author":"Varghese","year":"2021","journal-title":"Curr Oncol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021580","article-title":"Efficacy of physical exercise to offset anthracycline\u2212induced cardiotoxicity: a systematic review and meta\u2212analysis of clinical and preclinical studies.","volume":"10","author":"Naaktgeboren","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3109\/0284186X.2014.899435","article-title":"Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy.","volume":"53","author":"Klassen","year":"2014","journal-title":"Acta Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1249\/MSS.0000000000001970","article-title":"Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy.","volume":"51","author":"Foulkes","year":"2019","journal-title":"Med Sci Sports Exerc."},{"key":"B62","first-page":"223","article-title":"Effects of home-based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant chemotherapy (SAPA): a randomized controlled trial.","volume":"52","author":"Cornette","year":"2016","journal-title":"Eur J Phys Rehabil Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10549-017-4571-3","article-title":"Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.","volume":"168","author":"Mijwel","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijcard.2017.07.037","article-title":"Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: a proof-of-concept RCT.","volume":"245","author":"Kirkham","year":"2017","journal-title":"Int J Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-017-4554-4","article-title":"The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.","volume":"167","author":"Kirkham","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-01970-2","article-title":"A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.","volume":"21","author":"D\u00edaz-Balboa","year":"2021","journal-title":"BMC Cardiovasc Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ptj\/pzab014","article-title":"Attenuating treatment-related cardiotoxicity in women recently diagnosed with breast cancer via a tailored therapeutic exercise program: protocol of the atope trial.","volume":"101","author":"Postigo-Martin","year":"2021","journal-title":"Phys Ther."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07123-6","article-title":"Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol.","volume":"20","author":"Foulkes","year":"2020","journal-title":"BMC Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.e19123","article-title":"Impact of bolus versus continuous infusion of doxorubicin (DOX) on cardiotoxicity in patients with breast cancer and sarcomas: analysis of real-world data.","volume":"38","author":"Cranmer","year":"2020","journal-title":"J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes.","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics."},{"key":"B72","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity.","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy. clinical relevance and response to pharmacologic therapy.","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/circulationaha.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation."},{"key":"B75","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging.","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr."},{"key":"B77","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/s0008-6363(01)00513-2","article-title":"Relation between local myocardial growth and blood flow during chronic ventricular pacing.","volume":"53","author":"Van Oosterhout","year":"2002","journal-title":"Cardiovasc Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.amjcard.2007.12.037","article-title":"Usefulness of cardiac resynchronization therapy in the management of doxorubicin-induced cardiomyopathy.","volume":"101","author":"Ajijola","year":"2008","journal-title":"Am J Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.amjcard.2009.10.024","article-title":"Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy.","volume":"105","author":"Rickard","year":"2010","journal-title":"Am J Cardiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1001\/jama.2019.16658","article-title":"Association of cardiac resynchronization therapy with change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy.","volume":"322","author":"Singh","year":"2019","journal-title":"JAMA."},{"key":"B81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/heartjnl-2020-318333","article-title":"Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy","volume":"108","author":"Patel","year":"2022","journal-title":"Heart"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1542\/peds.2013-2272","article-title":"VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis.","volume":"134","author":"Cavigelli-Brunner","year":"2014","journal-title":"Pediatrics."},{"key":"B83","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/s1047951117002281","article-title":"Case report and review of the literature: the utilisation of a ventricular assist device as bridge to recovery for anthracycline-induced ventricular dysfunction.","volume":"28","author":"Krasnopero","year":"2018","journal-title":"Cardiol Young."},{"key":"B84","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/0391398818772497","article-title":"Recovery from anthracycline-induced cardiomyopathy with biventricular assist and valve repairs: a case report and literature review.","volume":"41","author":"Takami","year":"2018","journal-title":"Int J Artif Org."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1002\/ehf2.13362","article-title":"Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation.","volume":"8","author":"Guha","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B86","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the intermacs registry (interagency registry for mechanically assisted circulatory support).","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jaccao.2021.04.008","article-title":"Left ventricular assist devices in patients with active malignancies.","volume":"3","author":"Schlam","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCHEARTFAILURE.114.001292","article-title":"Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy.","volume":"7","author":"Oliveira","year":"2014","journal-title":"Circ Heart Fail."},{"key":"B89","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.amjcard.2012.10.048","article-title":"Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy.","volume":"111","author":"Lenneman","year":"2013","journal-title":"Am J Cardiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jaccao.2021.02.010","article-title":"Heart transplantation in adriamycin-associated cardiomyopathy in the contemporary era of advanced heart failure therapies.","volume":"3","author":"Ramu","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.1073\/pnas.1201608109","article-title":"Bax regulates primary necrosis through mitochondrial dynamics.","volume":"109","author":"Whelan","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B92","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.tibs.2011.08.009","article-title":"BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore.","volume":"36","author":"Walensky","year":"2011","journal-title":"Trends Biochem Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat Cancer."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation."},{"key":"B95","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1152\/ajpheart.01023.2001","article-title":"Melatonin as an effective protector against doxorubicin-induced cardiotoxicity.","volume":"283","author":"Liu","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/jpi.12176","article-title":"Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin.","volume":"57","author":"Govender","year":"2014","journal-title":"J Pineal Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s12276-020-00541-3","article-title":"Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPK\u03b12-dependent mitochondrial damage.","volume":"52","author":"Yang","year":"2020","journal-title":"Exp Mol Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/01.cir.91.1.10","article-title":"Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.","volume":"91","author":"Siveski-Iliskovic","year":"1995","journal-title":"Circulation."},{"key":"B99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2004.02.031","article-title":"Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury.","volume":"489","author":"Cao","year":"2004","journal-title":"Eur J Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/10715760802673008","article-title":"Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage.","volume":"43","author":"Tatlidede","year":"2009","journal-title":"Free Radic Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3892\/etm.2016.3437","article-title":"Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes.","volume":"12","author":"Liu","year":"2016","journal-title":"Exp Ther Med."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111702","article-title":"Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.","volume":"140","author":"Monahan","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/tox.22270","article-title":"Protective effect of co-enzyme Q10 on doxorubicin-induced cardiomyopathy of rat hearts.","volume":"32","author":"Chen","year":"2017","journal-title":"Environ Toxicol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/ajpheart.00253.2017","article-title":"Vitamin C mitigates oxidative\/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy.","volume":"313","author":"Akolkar","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1385\/ct:5:3:257","article-title":"Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction.","volume":"5","author":"Berthiaume","year":"2005","journal-title":"Cardiovasc Toxicol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0960327112467043","article-title":"N-acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats.","volume":"32","author":"Arica","year":"2013","journal-title":"Hum Exp Toxicol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0002-9149(85)90585-5","article-title":"Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs.","volume":"56","author":"Unverferth","year":"1985","journal-title":"Am J Cardiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4070\/kcj.2013.43.3.174","article-title":"Evaluation of short-term use of N-acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: EPOCH trial \u2013 a prospective randomized study.","volume":"43","author":"Jo","year":"2013","journal-title":"Korean Circ J."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96753","article-title":"Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.","volume":"3","author":"Asnani","year":"2018","journal-title":"JCI Insight."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/cbic.201900741","article-title":"Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy in a zebrafish heart-failure model.","volume":"21","author":"Lam","year":"2020","journal-title":"Chembiochem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ahj.2018.02.009","article-title":"Rationale and design of the SENECA (StEm cell iNjECtion in cAncer survivors) trial.","volume":"201","author":"Bolli","year":"2018","journal-title":"Am Heart J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaccao.2020.09.001","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial.","volume":"2","author":"Bolli","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaccao.2021.05.006","article-title":"Mitochondria-rich extracellular vesicles rescue patient-specific cardiomyocytes from doxorubicin injury.","volume":"3","author":"O\u2019Brien","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy.","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00075-1","article-title":"Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.","volume":"7","author":"Leong","year":"2017","journal-title":"Sci Rep."},{"key":"B116","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: cardiooncology state-of-the-art review.","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet."},{"key":"B119","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2021.09.008","article-title":"Potential applications for targeted gene therapy to protect against anthracycline cardiotoxicity: JACC: cardiooncology primer.","volume":"3","author":"Kok","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy.","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jat.782","article-title":"Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats.","volume":"21","author":"Abd El-Aziz","year":"2001","journal-title":"J Appl Toxicol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijcard.2005.08.061","article-title":"Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.","volume":"110","author":"Soga","year":"2006","journal-title":"Int J Cardiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3109\/10715762.2010.509399","article-title":"Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.","volume":"44","author":"Arozal","year":"2010","journal-title":"Free Radic Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1124\/jpet.115.225375","article-title":"Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy.","volume":"355","author":"Chen","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.","volume":"44","author":"de Nigris","year":"2008","journal-title":"Eur J Cancer."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5107193","article-title":"Dexrazoxane protects cardiomyocyte from doxorubicin-induced apoptosis by modulating miR-17-5p.","volume":"2020","author":"Yu","year":"2020","journal-title":"Biomed Res Int."},{"key":"B127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tox.2013.06.012","article-title":"Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.","volume":"311","author":"Jirkovsk\u00fd","year":"2013","journal-title":"Toxicology."},{"key":"B128","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1534735408322848","article-title":"Acute exercise protects against doxorubicin cardiotoxicity.","volume":"7","author":"Wonders","year":"2008","journal-title":"Integr Cancer Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1152\/ajpheart.01249.2004","article-title":"Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis.","volume":"289","author":"Ascens\u00e3o","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijcard.2004.11.004","article-title":"Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice.","volume":"100","author":"Ascens\u00e3o","year":"2005","journal-title":"Int J Cardiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy.","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.","volume":"18","author":"El-Shitany","year":"2012","journal-title":"J Card Fail."},{"key":"B135","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol."},{"key":"B136","first-page":"936","article-title":"Preventive effect of low-dose carvedilool combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer.","volume":"35","author":"Liu","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zui."},{"key":"B137","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/MAJ.0000000000000432","article-title":"Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity.","volume":"349","author":"Sun","year":"2015","journal-title":"Am J Med Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.863314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:51:44Z","timestamp":1650588704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.863314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":137,"alternative-id":["10.3389\/fcvm.2022.863314"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.863314","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"article-number":"863314"}}